Sept. 8, 2019 12:00 UTC 44% of patients achieved a response and nearly half (48%) maintained disease control at week 12 (efficacy as secondary endpoint) Treatment emergent adverse events Grade 3 or higher were reported by 10 of 25 patients (safety as primary endpoint)...
TYME-88-PANC Phase II study showed patients being treated with SM-88, who achieved at least an 80% reduction in circulating tumor cell burden, demonstrated a 60% decrease in risk of death SM-88 is an oral, investigational cancer metabolism-based therapy that has...
Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced that its confirmatory Phase 2 study of Bryostatin-1 in moderate to severe AD did...
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq: CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer biology, announced treatment of the first patient with an oral formulation of...
Clinical-stage pharma company Ocuphire Pharma, Inc has recently announced the completion of the first phase of their Two-Phase 2b Nyxol Eye Drops clinical studies, with the successful enrollment of 39 patients of glaucoma in the ORION-1 at 5 sites across the US from...
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting Program, an initiative which aims to further modernize drug development,...
Email
Text